Mayne Pharma Group Ltd shares are on fire

The Mayne Pharma Group Ltd (ASX: MYX) share price may have been one of the worst performers on the market in 2017, but so far in 2018 it has proven to be one of the best.

At the time of writing the pharmaceutical company’s shares are up over 6% to 78 cents, bringing its year-to-date return to an impressive 13%.

Why are its shares higher?

As there has been no news out of Mayne Pharma since its annual general meeting in November, I believe this recent rally can be attributed to the strong share price gain made by global generic drugs giant Teva Pharmaceuticals recently.

As Teva is the world’s largest generic drugs company, its share price performance tends to influence those of the smaller players like Mayne Pharma.

Since the start of the year the Teva share price has risen 16% thanks partly to a broker upgrade from Japanese investment bank Mizuho Securities. Its analysts responded positively to Teva’s presentation at a J.P. Morgan conference and clearly believe the worst is behind the company now.

Which in turn appears to have shifted investor sentiment positively for Mayne Pharma, much to the delight of its long-suffering shareholders.

Should you invest?

Whilst I do believe Mayne Pharma looks dirt cheap even after its recent rally, I intend to hold off an investment until its next update.

There will come a time when pricing pressures in the generic drug market ease and profit growth accelerates once again for Mayne Pharma, but I can’t help but feel its shares are too high risk until proof of this recovery has been seen,

In light of this, I would sooner invest in healthcare peers CSL Limited (ASX: CSL) and ResMed Inc. (CHESS) (ASX: RMD). But I will be watching the company very closely through earnings season.

As well as CSL and ResMed, I think these top growth shares are in the buy zone today.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.